Bone marrow grafts

Dreger P, Kloss M, Petersen B, Haferlach T, et al. 1995. -Autologous progenitor cell transplantation Prior exposure to stem cell-toxic drugs determines yield and engraft-ment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 86 3970-3978. 

Ohlen, C., Kling, G., Hoglund, P., Hansson, M., Scangos, G., and Bieberich, C. et al. (1989). Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice. Science 246(4930), 666-668. 

Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990 75(3) 781-6. 

Of 80 patients who received cyclophosphamide 50 mg/ kg/day for 4 days in preparation for bone marrow grafting 17% had symptoms consistent with cyclophosphamide cardiotoxicity (6). Six died from congestive heart failure. Older patients were at greatest risk of developing cardiotoxicity. 

Mathe G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. BMJ 1970 2 131-136. 

Goel, A., Sangwan, S., Siwach, R., Ali, A. 2005. Percutaneous bone marrow grafting for the treatment of tibial non-union. Injury 36(1), 203-206. 

Protein replacement has long been used in the therapy of hemophilia and hemorrhage. A direct enzyme replacement has been successful in animals where it has been possible to correct UDP-glucuronyl transferase deficiencies in mice or rats but in humans, enzyme administration has met with little success. Enzymes can also be administered by transfusion of leukocytes or by bone marrow grafts, which have been particularly successful in some cases of agammaglobulinemia. 

Potentially, bone marrow transplantation should offer the best possibility of long term survival for patients with aplastic anaemia or severe combined immunodeficiency disease. However, with bone marrow, grafts there is not only the problem of incompatibility of the graft with the recipient, but also the... 

In this research, diabetic mice were created by injection streptozocin. After that, they were treated by one of three approaches grafting allogenic bone marrow, grafting mesenchymal stem cells, grafting insulin producing cells differentiated from mesenchymal stem cells. 

---